Defense Secretary Pete Hegseth has ordered annual testosterone-deficiency screening for active-duty and reserve service members age 30 and older. He says the program will help troops operate at their best and strengthen military readiness. Treatment after a test will be voluntary. The blood draw is mandatory policy; the medical benefit remains an unproved claim. [1]
Reuters asked six men's-health specialists to examine that claim. Five questioned the announcement or warned that broad testing could lead to unnecessary or harmful treatment. Four said there was no solid evidence that screening everyone in the covered military population would optimize combat readiness. Their distinction is basic but consequential: evidence from patients tested because they had symptoms does not automatically support testing an entire population. [1]
The policy compresses several decisions into one word, readiness. A screening result is not a diagnosis. A diagnosis is not a treatment recommendation. A voluntary prescription is not a measured gain in stamina, resilience or military performance. The Pentagon has announced the first step without publishing detailed guidance for evaluating an abnormal result or explaining whether the same process will apply to male and female service members. [1]
That missing middle matters because testosterone treatment can affect fertility. The specialists interviewed by Reuters also raised overtreatment concerns. Service members may receive a number, hear that it is connected to performance and reasonably assume that raising it is the mission. Voluntary treatment does not remove that institutional pressure; it makes the quality of counseling, repeat confirmation and informed consent more important. [1]
Hegseth has presented the program as preventive capacity rather than an answer to a measured failure. Yet the public order supplies no baseline showing how many covered troops have a confirmed deficiency, how many have relevant symptoms or which readiness measure the annual test is expected to improve. Without those denominators, the Pentagon will be able to count tests and perhaps prescriptions long before it can count useful outcomes.
The order may produce information. It may identify people who need a fuller clinical evaluation, and a broad program could create a dataset about a younger military population. Neither possibility establishes the policy's benefit in advance. Collection, diagnosis and evidence are different achievements.
Military medicine also changes the meaning of an ordinary clinical invitation. A civilian patient can decline a test without wondering whether the decision will enter a readiness file. A service member receives the order inside a hierarchy that evaluates fitness and deployability. Even when treatment is voluntary, the department must explain who sees the result, what enters a personnel record and whether declining a recommendation carries any consequence. The public order answers none of those implementation questions.
Nor can annual repetition supply its own justification. A program may become routine because it is easy to count, not because the count changes care. The Pentagon should publish the baseline, the rate of confirmed findings after evaluation, the number of people counseled without treatment and the readiness outcome it intends to compare. Otherwise a growing test total will look like progress while the clinical and military questions remain exactly where they began.
The next documents should define the evaluation path and the performance test. They should say who interprets results, how service members receive fertility counseling, how privacy is protected and what outcome would justify another year of universal screening. If the Pentagon calls testosterone a readiness instrument, it owes the force more than a laboratory value. It owes evidence that the instrument measures what the department says it will improve.
-- SAMUEL CRANE, Washington